Evidence map›Paper›PMID 39208918›Full record

ArticleJournal of vascular surgery2025

Markers of optimal medical therapy are associated with improved limb outcomes after elective revascularization for intermittent claudication.

Marissa C Jarosinski, Muhammed S Hafeez, Natalie D Sridharan, Elizabeth A Andraska, Joseph M Meyer, Yekaterina Khamzina, Edith Tzeng, Katherine M Reitz

Abstract read
In one paragraph

Article in Journal of vascular surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Frailty Screening Using the Risk Analysis Index: A User Guide.Joint Commission journal on quality and patient safety · 2025
    Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Marissa C JarosinskiDivision of Vascular Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA.
Muhammed S HafeezDivision of Vascular Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA.
Natalie D SridharanDivision of Vascular Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA.
Elizabeth A AndraskaDivision of Vascular Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA.
Joseph M MeyerDivision of Cardiology, Johns Hopkins Hospital, Baltimore, MD.
Yekaterina KhamzinaDepartment of Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA.
Edith TzengDivision of Vascular Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA.
Katherine M ReitzDivision of Vascular Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA. Electronic address: reitzkm2@upmc.edu.

Funding

Vascular Surgery Research Training (VascTrain) ProgramT32HL098036 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Edith Tzeng · 2010 to 2026
$7.2M
Summer Research in Vascular Surgery (SRVS)T35HL155018 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Edith Tzeng · 2022 to 2026
$176k
NHLBI NIH HHS T32 HL098036NHLBI NIH HHS T35 HL155018
6 · The paper itself

Abstract

backgroundOptimal medical therapy (OMT) is a modifiable factor that decreases mortality and cardiovascular events in patients with severe peripheral arterial disease. We hypothesized that preintervention OMT would be associated with improved 1-year reintervention and major adverse limb event (MALE) rates after elective endovascular revascularization for intermittent claudication (IC).

methodsUsing the Vascular Quality Initiative (2010-2020), we identified patients with IC undergoing elective endovascular, hybrid, and open surgical interventions. Preoperative antiplatelet, statin, and nonsmoking status defined OMT components and created three groups: complete (all components), partial (1-2 components), and no OMT. The primary outcome was 1-year reintervention. Secondary outcomes included MALE and factors associated with OMT usage. Multivariable logistic regression generated adjusted odds ratios (aOR).

resultsThere were 39,088 patients (14,907 [38.1%] complete, 22,054 [56.4%)] partial, 2127 [5.4%] no OMT) who met our criteria. Patients with any OMT were more frequently older with more cardiovascular diseases and diabetes (P < .0001). Patients without OMT were more likely to be Black or with Medicare or Medicaid (P < .05). Observed 1-year reintervention (5.3% complete OMT, 6.1% partial OMT, 8.3% no OMT; P < .001) and MALE (5.6% complete OMT, 6.3% partial OMT, 8.8% no OMT; P < .001) were decreased by partial or complete OMT compared with no OMT. Complete OMT significantly decreased the adjusted odds of reintervention and MALE by 28% (aOR, 0.72, 95% confidence interval [95% CI], 0.59-0.88) and 30% (aOR, 0.70; 95% CI, 0.58-0.85), respectively, compared with no OMT. Partial OMT decrease the adjusted odds of reintervention and MALE by 24% (aOR, 0.76; 95% CI, 0.63-0.92) and 26% (aOR, 0.74; 95% CI, 0.62-0.89), respectively.

conclusionsPreintervention OMT is an underused, modifiable risk factor associated with improved 1-year reintervention and MALE. Vascular surgeons are uniquely positioned to initiate and maintain OMT in patients with IC before revascularization to optimize patient outcomes.

Indexed as

Endovascular ProceduresIntermittent ClaudicationPeripheral Arterial DiseaseAgedAged, 80 and overAmputation, SurgicalDatabases, FactualElective Surgical ProceduresFemaleHumansLimb SalvageMaleMiddle AgedPlatelet Aggregation InhibitorsRegistriesRetrospective StudiesPlatelet Aggregation InhibitorsAntiplateletIntermittent claudicationLimb outcomesMajor adverse limb eventsPeripheral artery diseaseRevascularizationSmoking cessationStatinVascular Quality Initiative

Identifiers

PMID39208918
PMCPMC11684783

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.